Role of testosterone in managing advanced prostate cancer.
Androgen deprivation therapy is frequently used to treat patients with advanced prostate cancer. New therapies for metastatic castration-resistant prostate cancer have drawn increased attention to serum and intratumoral testosterone levels. The present review examines the role of testosterone in prostate cancer progression, discusses the nuances and potential pitfalls in measuring serum testosterone using available assays, and summarizes current data relevant to the arguments for and against achieving and maintaining the lowest possible testosterone levels during androgen deprivation therapy, including the adverse effects of such treatment. Incorporating this information, we have made recommendations incorporating testosterone evaluation and its effect on the clinical decision-making process.
University of Colorado Denver, Anschutz Medical Campus, Aurora, CO, USA. kyle.rove@ucdenver.edu
Kyle O
KO
Rove
Frans M
FM
Debruyne
Bob
B
Djavan
Leonard G
LG
Gomella
Hari K
HK
Koul
M Scott
MS
Lucia
Daniel P
DP
Petrylak
Neal D
ND
Shore
Nelson N
NN
Stone
E David
ED
Crawford
D000726:Androgen Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D001774:Blood Chemical Analysis; D018450:Disease Progression; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists*; D006801:Humans; D008297:Male; D017410:Practice Guidelines as Topic; D011471:Prostatic Neoplasms / Q000097:blood* / Q000188:drug therapy*; D013739:Testosterone / Q000037:antagonists & inhibitors / Q000097:blood*
D000726:Androgen Antagonists; D007987:Gonadotropin-Releasing Hormone; D013739:Testosterone